Drug combo aims to outsmart resistant lung cancer
NCT ID NCT02321501
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests the combination of two oral drugs, ceritinib and everolimus, in people with advanced solid tumors or a specific type of lung cancer (ALK-positive NSCLC) that has stopped responding to standard treatments. The main goal is to find a safe dose and look for early signs that the combination can shrink tumors or slow disease progression. Only 37 participants are enrolled, so results will be preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ceritinib and everolimus
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors or ALK-positive lung cancer who have run out of standard therapies.
- What could go wrong
- This is a very early, small Phase I trial focused on safety and dosing, not on proving the combination works. Side effects from two cancer drugs together could be significant, and many early combinations fail to show enough benefit to move forward.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK-POSITIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Vaccine trains immune system to hunt down cancer cells
- New study aims to tame cholesterol side effect of lung cancer drug
- Targeted drug shows promise for Gene-Driven lung cancers
- Lung cancer drug shows promise in keeping tumors at bay after chemo
- Gut radiation may revive immunotherapy in resistant cancers